Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Schibsted Media in connection with its acquisition of TV4 and MTV Finland
Mandate

Vinge advises Schibsted Media in connection with its acquisition of TV4 and MTV Finland

February 25, 2025 M&A Commercial Agreements Intellectual Property Data protection and processing of personal data Employment and Benefits Real Estate and Construction FDI EU, Competition and Regulatory Corporate Crime & Compliance Carve-Outs

Schibsted Media has entered into an agreement to acquire Telia Company’s TV & Media business, consisting of TV4 and MTV Finland. The transaction implies an enterprise value of SEK 6.55 billion on a cash and debt-free basis and it is expected to close in Q3 2025, subject to customary regulatory approvals.

Vinge’s team consisted mainly of Johan Larsson, Johan Winnerblad, Jesper Ottergren, Per Kling, Nathalie Wikman (M&A), Eva Fredrikson, Martin Boström, Elis Allmark,  Mario Saad (Commercial agreements), Malin Malm Waerme, Arvid Axelryd, Ian Jonson, Alva Skott, Melinda Oldenburg (Intellectual property), Nicklas Thorgerzon (GDPR), Sam Seddigh, Emil Lindwall, Agnes Pigg (Employment and benefits), Kristoffer Larson, Sara Franson (Real estate), Marcus Glader, Fredrik Hellström, Jakob Jeanrond, Martin Bergqvist, Martin Hammarskiöld (Competition and FDI), Martin Johansson, Carl Johan af Petersens, Hampus Peterson (Compliance and regulatory).

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026